Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Principia Biopharma Inc (PRNB)

Principia Biopharma Inc (PRNB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,672,896
  • Shares Outstanding, K 33,009
  • Annual Sales, $ 35,160 K
  • Annual Income, $ -53,790 K
  • 60-Month Beta 0.77
  • Price/Sales 52.28
  • Price/Cash Flow N/A
  • Price/Book 5.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.79
  • Number of Estimates 4
  • High Estimate -0.67
  • Low Estimate -0.85
  • Prior Year -0.57
  • Growth Rate Est. (year over year) -38.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.21 +22.99%
on 03/18/20
69.17 -26.73%
on 03/05/20
-12.41 (-19.67%)
since 02/27/20
3-Month
41.21 +22.99%
on 03/18/20
75.65 -33.01%
on 02/11/20
-9.02 (-15.11%)
since 12/27/19
52-Week
25.35 +99.92%
on 10/02/19
75.65 -33.01%
on 02/11/20
+15.87 (+45.59%)
since 03/27/19

Most Recent Stories

More News
Principia Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results

Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced financial results for the fourth quarter and...

PRNB : 50.68 (-9.00%)
Earnings Preview: Principia Biopharma Inc. (PRNB) Q4 Earnings Expected to Decline

Principia Biopharma Inc. (PRNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNB : 50.68 (-9.00%)
Principia to Present at 9th Annual SVB Leerink Global Healthcare Conference

Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced that management will participate in the...

PRNB : 50.68 (-9.00%)
Sahm Adrangi's Kerrisdale Capital Issues Negative Report on Principia Biopharma Inc. and Announces Conference Call Schedule

Kerrisdale Capital, a private investment manager, has published a report explaining its short position in Principia Biopharma Inc. (NASDAQ: PRNB), a biopharmaceutical company whose $2 billion valuation...

PRNB : 50.68 (-9.00%)
PRNB Crosses Above Average Analyst Target

In recent trading, shares of Principia Biopharma Inc have crossed above the average analyst 12-month target price of $54.00, changing hands for $55.23/share. When a stock reaches the target an analyst...

PRNB : 50.68 (-9.00%)
Principia Announces Expansion of its BTK Franchise with PRN473 Topical

Company expands focus on immune-mediated diseases and suspends FGFR program

PRNB : 50.68 (-9.00%)
Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases

Company's lead candidate PRN1008 receives generic name -- rilzabrutinib

PRNB : 50.68 (-9.00%)
Principia Updates PRN1008 Pemphigus Clinical Program

Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immune-mediated diseases,...

PRNB : 50.68 (-9.00%)
PRNB Crosses Above Average Analyst Target

In recent trading, shares of Principia Biopharma Inc have crossed above the average analyst 12-month target price of $48.33, changing hands for $48.90/share. When a stock reaches the target an analyst...

PRNB : 50.68 (-9.00%)
Principia Presents Consistent Positive Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial

Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced consistent positive data from an ongoing...

PRNB : 50.68 (-9.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade PRNB with:

Business Summary

Principia Biopharma Inc. is a clinical stage biopharmaceutical company. It offers reversible covalent small molecule drugs for the treatment of cancers. The company's product pipeline consists of PRN1008, PRN1371 and PRN2246 which are in clinical stage. Principia Biopharma Inc. is based in San Francisco,...

See More

Key Turning Points

2nd Resistance Point 55.67
1st Resistance Point 53.17
Last Price 50.68
1st Support Level 49.43
2nd Support Level 48.19

See More

52-Week High 75.65
Fibonacci 61.8% 56.44
Last Price 50.68
Fibonacci 50% 50.50
Fibonacci 38.2% 44.56
52-Week Low 25.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar